✅ Insurers often deny coverage for GLP-1 weight loss drugs, despite evidence of their effectiveness and value. A University of Mississippi study suggests insurers need to offer more than just the medication for long-term cost savings.

✅ Research indicates GLP-1s like Ozempic, Wegovy, and Zepbound are cost-effective, but their widespread use could still strain insurer budgets due to the large eligible patient population (40% of Americans are obese).

✅ Long-term cost savings from GLP-1s are not yet proven, as patients often stop treatment within a year and regain weight. For effectiveness, continuous support like dietitians and fitness programs, not just medication, is crucial.

✅ Compounded GLP-1 versions, while cheaper, carry significant risks due to unverified ingredients and manufacturing processes, prompting FDA warnings. Consulting a physician is advised for safety and to ensure FDA-approved medication.

#GLP1 #Healthcare #Obesity

GLP-1 weight-loss drugs linked to “low” but real risk of hair loss, study finds. Importantly, the most observed cases of hair loss linked to GPL-1 were reversible, as hair follicles remained intact, the authors said.

Read Full Article

#GLP1 #HairLoss #WeightLossMedication

📊 New study in The BMJ reveals GLP-1 drugs, used for type 2 diabetes and obesity, are linked to a higher risk of hair loss compared to other diabetes medications.

📈 The risk is 37% higher than with SGLT-2 inhibitors and 68% higher than with DPP-4 inhibitors.

🌱 Most reported cases of hair loss were reversible, as hair follicles remained intact.

🤔 Researchers suggest rapid weight loss, calorie restriction, and hormonal changes associated with GLP-1 therapy may contribute to hair shedding.

#GLP1 #Diabetes #HairLoss

GLP-1 use rising rapidly among U.S. adolescents, young adults. Severe obesity among adolescents and young adults has increased substantially over the past two decades, currently affecting about 9% of people between ages 12 and 18. Among adults, the rate of severe obesity increased from 5% to 10%.

Read Full Article

#GLP1 #AdolescentHealth #ObesityPrevention

📈 U.S. adolescents & young adults are increasingly using GLP-1 weight-loss drugs, with exclusive use rising from 88.2% (May-Nov 2022) to 96.1% (June 2025-Jan 2026) among those treated for obesity. Metabolic and bariatric surgery (MBS) rates decreased from 11.6% to 3.7% in the same periods.

🧑‍⚕️ UT Southwestern researchers analyzed data from over 204,000 individuals aged 13-25 treated for obesity between May 2022 and January 2026. This study is the first national-scale analysis of combined GLP-1RA therapy and MBS in this age group.

💡 The findings highlight an "inflection point" in pediatric obesity treatment and emphasize the urgent need for evidence-based clinical guidelines to guide the integration of GLP-1 medications and bariatric surgery in youth.

#ObesityTreatment #GLP1 #Healthcare

GLP-1 drugs like Ozempic may help clear Alzheimer’s disease plaques, new systematic review suggests. By analyzing dozens of laboratory and animal studies, researchers found that GLP-1 receptor agonists consistently lower the brain proteins responsible for the progression of this dementia.

Read Full Article

#Alzheimers #GLP1 #DementiaResearch

GLP-1 weight loss drugs such as Ozempic are linked with a lower risk of age‐related macular degeneration (AMD), a common eye disease that is the leading cause of irreversible vision loss in older adults.

Read Full Article

#Ophthalmology #GLP1 #AgeRelatedMacularDegeneration

👁️ A new study in Diabetes, Obesity and Metabolism found GLP-1 drugs (like Ozempic) are linked to an 18% lower risk of age-related macular degeneration (AMD) in adults aged 60+ with obesity but no diabetes.

🔬 Researchers analyzed data from over 157,000 matched patients, comparing GLP-1 users to those on other weight-loss medications.

🤔 While the exact mechanism is unclear, potential reasons include a direct protective effect on the retina by reducing inflammation, or that greater weight loss achieved with GLP-1s contributes to reduced risk.

#GLP1 #Ozempic #EyeHealth

Study finds GLP1 semaglutide reduced systemic inflammation within weeks, before substantial weight loss, and lowered MACE (major adverse cardiovascular events) risk even without weight loss

Read Full Article

#GLP1 #Semaglutide #CardiovascularHealth

GLP-1 users showed lower tuberculosis risk across a large multi-country health-record study

Read Full Article

#GLP1 #Tuberculosis #HealthRecordsStudy

Weight loss drugs may help with mental health. People with bipolar disorder who were taking semaglutide (otherwise known as Ozempic or Wegovy), a type of GLP-1 medication, had significantly lower rates of psychiatric hospitalization compared with periods when they were not taking GLP-1 medications,"

Read Full Article

#MentalHealth #WeightLossDrug #GLP1疗法

🐁 A new study in mice suggests semaglutide (Wegovy, Ozempic) can extend lifespan by about 12 percent when started in old age.

💪 In mice, semaglutide showed benefits in maintaining memory and blood sugar control, outperforming dieting in these areas.

🧬 Researchers found semaglutide mimics calorie restriction by reducing inflammation and improving blood sugar regulation, but also shows added benefits for memory and curiosity.

#GLP1 #Longevity #Semaglutide

GLP-1 use among young children with obesity in US remains rare but is rising rapidly. The number is 310 times higher in June 2026 than it was in 2019, when the drugs were initially prescribed. An estimated 20 percent of children in the US have obesity

Read Full Article

#PediatricObesity #GLP1 #ChildHealthScience

GLP-1 drugs may improve obstructive sleep apnea through mechanisms beyond weight loss, including effects on breathing control, upper-airway neuromuscular function, and inflammation

Read Full Article

#GLP1 #SleepApnea #ObstructiveSleepApnea

💡 Activating the GLP-1 receptor, a target of popular weight-loss and diabetes drugs, is linked to better mental health and a lower risk of depression and bipolar disorder, according to a new genetic study published in Translational Psychiatry.

🧠 The research, led by Guoyi Yang, used genetic variations to mimic the effect of GLP-1 receptor activation, suggesting psychiatric benefits may go beyond weight loss.

📉 A 1 kg/m² decrease in BMI due to GLP-1 pathway activation was associated with an 18% lower risk of major depressive disorder and a 39% lower risk of bipolar disorder.

#GLP1 #MentalHealth #MedicalResearch

A large study shows that patients taking Ozempic-like GLP-1 drugs face an 11 times higher risk of vomiting or inhaling stomach contents into their lungs under anesthesia, as the medication delays stomach emptying, leaving food behind despite fasting.

Read Full Article

#GLP1 #OzempicSideEffects #AnesthesiaRisks

Olive Oil Before Oral Glucose Delays Gastric Emptying and Lowers Glycemia Through Partially Redundant Glucagon and GLP-1 Signaling in Mice

Read Full Article

#OliveOil #GlycemicControl #GLP1

GLP1 treatment linked to lower risk of hospitalization and death in older adults with fatty liver disease. Patients taking GLP1 had a 28% lower risk of hepatic decompensation and a 45% lower risk of death from any cause.

Read Full Article

#GLP1 #FattyLiverDisease #HealthcareInnovation

Nearly half of people who started GLP-1 drugs like Ozempic or Wegovy say they now drink less alcohol, and among heavier drinkers it was over half (54%), according to a new national US survey of 2,000+ adults published in JAMA Psychiatry. The drugs may act on the brain's craving and reward pathways.

Read Full Article

#GLP1 #OzempicWegovy #AlcoholUseImpact

Scientists used AI to read ~150,000 Reddit posts from people taking gray-market retatrutide, an unapproved next-gen weight-loss drug. Top reported side effect wasn't nausea like in trials, but increased appetite, plus more sleep problems, a racing heart and muscle changes than other GLP-1 users.

Read Full Article

#WeightLossDrug #GLP1 #RedditStudy